1. Introduction {#sec1}
===============

Glioblastoma multiforme (GBM) is the most malignant form of astrocytoma and the most frequent primary tumor of the brain in adults. Its prognosis is poor, with a median survival of 12.1--14.6 months despite current multimodal treatment \[[@B1]\]. GBM shows a great degree of histological variability and numerous morphologic subtypes, some of which may be associated with specific genetic alterations or clinical behaviors \[[@B2]\]. Glioblastoma with primitive neuronal component, which has been referred to as glioblastoma with the primitive neuroectodermal tumor-like component (GBM-PNET) in the literature and which is one of the emerging GBM subtypes, is a rare tumor with the combined features of malignant glioma and PNET. Here, we report a long-term survival patient who presented not only this rare collision tumor but also different histopathological components in the disease course.

2. Case Presentation {#sec2}
====================

A 23-year-old woman presented with progressive headache, nausea, and vomiting for 1 week. Right-side weakness, ptosis, and diplopia were also found. Due to acute onset conscious disturbance (Glasgow Coma Scale of E3VaM5) in the hospital, brain computed tomography was arranged and revealed an enhanced brain tumor with necrotic cystic change. This tumor was located at the left temporal lobe with upward extension to the left basal ganglion and periventricular region, causing perifocal edema and midline shift ([Figure 1](#fig1){ref-type="fig"}). We performed emergent craniectomy for tumor removal in December 2006.

Pathology revealed pleomorphic, hyperchromatic cells with glassy, astrocytic cytoplasm, as well as hypercellularity, microvascular proliferation, and necrosis, consistent with the diagnosis of classic GBM ([Figure 2](#fig2){ref-type="fig"}).

The patient underwent radiotherapy 1 month later and followed by chemotherapy with temozolomide for 6 months. Her performance status improved to a Karnofsky Grade of 70, and her clinical condition was stable thereafter. However, follow-up brain magnetic resonance imaging (MRI) in June 2014 revealed a new enhanced nodular lesion, approximately 1.1 cm in diameter, at the left temporal base. The brain MRI in October 2014 revealed a progressive change of lesions, maximum 3.0 cm in diameter ([Figure 1](#fig1){ref-type="fig"}). Thus, she again received surgery for gross tumor removal.

Histologically, except for the necrosis feature of GBM, the tumors showed the oligodendroglial component. Neoplastic cells also showed isocitrate dehydrogenase 1(IDH1)(+), p53(diffuse +), and O^6^-methylguanine-DNA methyltransferase (MGMT)(−) as revealed by immunostaining ([Figure 3](#fig3){ref-type="fig"}).

During follow-up, signs of increased intracranial pressure were noted in May 2015. Therefore, she received a third debulking surgery. The third pathology revealed both GBM- and PNET-like components. In immunohistochemistry, the PNET-like component exhibited positivity for synaptophysin and CD56 and focal weak positivity for glial fibrillary acidic protein (GFAP) ([Figure 4](#fig4){ref-type="fig"}).

One month after the surgery, her condition rapidly deteriorated. The patient and her family chose to pursue hospice care. She passed away with a total 9-year survival since diagnosis ([Table 1](#tab1){ref-type="table"}).

3. Discussion {#sec3}
=============

According to the current 2016 WHO classification system, GBM can be divided into IDH wild type, IDH mutant, and NOS (not otherwise specified). Giant cell glioblastoma, gliosarcoma, and epithelioid glioblastoma are categorized under IDH wild-type glioblastoma \[[@B3]\]. Moreover, based on the described histopathology, diverse glioblastoma variants are still emerging, such as glioblastoma with primitive neuroectodermal tumor-like component (GBM-PNET), GBM with oligodendroglioma component (GBM-O), small cell astrocytoma, and granular cell astrocytoma \[[@B2]\]. Recent studies have suggested that under the stochastic or hierarchical hypothetical model, the presence of a cancer stem cell may account for the substantial diversity in the pathological characteristics of GBM \[[@B4]\].

GBM-Os account for 4% to 27% of all GBMs in previous studies. They feature both astrocytic and oligodendroglial differentiation, with the typical fried-egg appearance. Recent analyses of large tumor databases found a significantly higher IDH1 mutation rate in GBM-Os (31% versus \<5%) \[[@B5]\]. Moreover, the EORTC 26981/NCICCE.3 trial found that GBM-Os showed significantly higher levels of IDH1 mutation (19% versus 3%) than GBMs \[[@B6]\]. Thus, GBM-Os exhibit a higher frequency of IDH1 mutations and a lower frequency of PTEN deletions, which is a characteristic distinct from that of classic GBMs. Recent studies have revealed that GBM-Os tend to occur at a younger age and that patients with GBM-Os exhibit longer survival than those with other forms of GBMs \[[@B7], [@B8]\].

In contrast to GBMs, those previously designated as PNETs, incorporated into the term embryonal tumor with multilayered rosettes (ETMR) in the 2016 WHO classification system for CNS tumors, are aggressive neoplasms, with medulloblastoma-like histology, and mostly affect the pediatric population. They are composed of poorly differentiated neuroepithelial cells and are associated with a high risk of metastases through cerebrospinal fluid dissemination. Patients with PNETs exhibit a poor prognosis, requiring craniospinal radiation in addition to platinum-based chemotherapy \[[@B3], [@B9]\]. GBM-PNETs are a rare pattern in GBMs. They contain the architectures of both traditional GBM and PNET-like areas, with hypercellularity, minimal fibrillary background, high nuclear-to-cytoplasmic ratio, oval-round hyperchromatic nuclei, high mitotic-karryorhectic indices, and Homer Wright neuroblastic rosettes. Furthermore, PNET-like areas show lower GFAP expression but positive staining for S-100, synaptophysin, NeuN, and neurofilament protein (NFP) \[[@B10]--[@B12]\].

One of the largest series on GBM-PNETs reported 53 cases, with a male : female ratio of 1.3, leptomeningeal metastasis in up to 40% of patients, and the median survival of 9.1 months \[[@B11]\]. However, recent studies have suggested favorable prognostic features for GBM-PNETs. A study of 40 cases of grade III or IV glioma with PNET components, as demonstrated by GFAP and NFP coexpression, reported a low recurrence rate (36%) and a mean survival of 44 months after gross total resection \[[@B12]\]. In another study of 12 patients with GBM-PNETs, IDH1 mutations were observed in 2 patients with an overall survival of 15 and 31 months. The present study also concluded that GBM-PNETs have a higher frequency of IDH1 mutation and might have favorable prognosis \[[@B13]\].

In our case, we observed different pathological variants of glioblastoma in the disease course. Both histopathologic types of GBM-Os and GBM-PNETs tend to contribute to a favorable prognosis. In addition, probably because of initial radical surgical resection, young age at the time of diagnosis, silencing of MGMT, and positive IDH-1 staining, the patient had long-term survival.

4. Conclusion {#sec4}
=============

GBM is associated with substantial diversity in its clinicopathological characteristics. GBM-Os resemble GBMs but also contain areas resembling oligodendroglioma, whereas GBM-PNETs are rare tumors with the combined features of high-grade glioma and primitive neuroectodermal tumors. This report illustrates that the distinct histopathologic variants of glioblastoma can appear throughout the disease course and such tumors are associated with favorable outcomes.
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![(a) Brain computed tomography in December 2006 showed an enhanced brain tumor over the left temporal region with mass effect; (b) no obvious recurrent tumor was found by brain MRI in 2013; (c) recurrent tumor was found by MRI in 2014, before the second surgery; and (d) brain MRI in May 2015, before the third surgery, revealed tumor progression.](CRIS2018-1382680.001){#fig1}

![(a) Markedly increased cellularity of neoplastic astrocytes with nuclear pleomorphism and hyperchromasia (200x), (b) microvascular proliferation (200x), (c) necrosis (200x), and (d) increased proliferation index of tumor cells as revealed by Ki-67 immunostaining (16.3%) (100x).](CRIS2018-1382680.002){#fig2}

![(a) Foci of oligodendroglial component featuring clear cytoplasm, round nuclei (200x). The neoplastic cells showed (b) necrosis (100x), (c) GFAP(+) (100x), (d) p53(+) (100x), and (e) IDH1(+) (100x).](CRIS2018-1382680.003){#fig3}

![(a) Neoplastic cells with nuclear pleomorphism, hyperchromatism, abundant mitosis, and apoptosis (200x). Immunohistochemistry revealed (b) focal weak positivity for GFAP (200x), (c) synaptophysin(+) (400x), and (d) CD56(+) (400x).](CRIS2018-1382680.004){#fig4}
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Timeline.

  ---------------------------------- ---------------------------------------------------------------------------- ------------------------------------------------------------------------ -------------------------------------------
  Dates                              Relevant past medical history and interventions                                                                                                       
                                                                                                                                                                                           
  December 2006                      23 y/o female with progressive headache, nausea, and vomiting for one week                                                                            
                                                                                                                                                                                           
  Date                               Summaries from initial and follow-up visits                                  Diagnostic testing (including dates)                                     Interventions
                                                                                                                                                                                           
  December 20, 2006                  Right-side weakness, ptosis and diplopia, conscious drowsiness               Brain CT                                                                 Emergent craniectomy for removal of tumor
                                     Pathology: classic GBM                                                                                                                                
  January 18, 2007\~March 07, 2007                                                                                                                                                         RT
  March 2007\~January 2008                                                                                                                                                                 6 courses of Temadol
  June 09, 2011                                                                                                                                                                            Cranioplasty
  October 10, 2014                                                                                                MRI---progressive change of several tumors over the left temporal base   
  December 02, 2014                                                                                                                                                                        Craniotomy for tumor removal
                                     Pathology---glioblastoma multiforme, with oligodendroglial component                                                                                  
  May 07, 2015                       Headache, nausea, and vomiting                                               MRI---tumor local recurrence, with ventricle seeding                     
  May 13, 2015                                                                                                                                                                             Craniotomy for tumor removal
                                     Pathology---glioblastoma multiforme with PNET-like component                                                                                          
  June 2015                          Signs of increased intracranial pressure                                     Brain CT: tumor progression                                              Conservative treatment
  July 16, 2015                      Expired                                                                                                                                               
  ---------------------------------- ---------------------------------------------------------------------------- ------------------------------------------------------------------------ -------------------------------------------
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